Deutsche Bank Ag\ Vaxart, Inc. Transaction History

Deutsche Bank Ag\

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.6 - $1.41 $66,269 - $155,733	-110,449 Reduced 70.8%	45,546 $33,000
Q1 2023 May 15, 2023	BUY	$0.71 - $1.25 $74,608 - $131,353	105,083 Added 206.4%	155,995 $118,000
Q4 2022 Feb 13, 2023	BUY	$0.75 - $2.24 $620 - $1,852	827 Added 1.65%	50,912 $48,000
Q3 2022 Nov 14, 2022	SELL	$2.09 - $4.5 $32,307 - $69,561	-15,458 Reduced 23.58%	50,085 $109,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $5.28 $34,754 - $67,964	-12,872 Reduced 16.42%	65,543 $229,000
Q1 2022 May 13, 2022	SELL	$4.29 - $6.64 $30,888 - $47,808	-7,200 Reduced 8.41%	78,415 $395,000
Q4 2021 Feb 11, 2022	SELL	$5.77 - $7.96 $85,788 - $118,349	-14,868 Reduced 14.8%	85,615 $537,000
Q3 2021 Nov 04, 2021	BUY	$6.67 - $9.8 $113,990 - $167,482	17,090 Added 20.49%	100,483 $798,000
Q2 2021 Aug 11, 2021	BUY	$5.06 - $10.78 $201,711 - $429,733	39,864 Added 91.58%	83,393 $625,000
Q1 2021 May 13, 2021	SELL	$5.64 - $23.33 $147,311 - $609,356	-26,119 Reduced 37.5%	43,529 $263,000
Q4 2020 Feb 16, 2021	BUY	$3.5 - $7.98 $130,518 - $297,582	37,291 Added 115.25%	69,648 $398,000
Q3 2020 Nov 12, 2020	BUY	$4.78 - $16.97 $47,025 - $166,950	9,838 Added 43.69%	32,357 $215,000
Q2 2020 Aug 13, 2020	BUY	$1.68 - $8.85 $37,831 - $199,293	22,519 New	22,519 $199,000
Q1 2020 May 14, 2020	SELL	$0.34 - $2.87 $3,686 - $31,122	-10,844 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$0.28 - $0.39 $3,032 - $4,224	10,832 Added 90266.67%	10,844 $3,000
Q1 2018 May 15, 2018	BUY	$4.95 - $9.02 $59 - $108	12 New	12 $0

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.